EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk

Hanin Diab iD, Taylor Fuquay iD, Palika Datta, Ulrich Bickel iD, Jonathan Thompson iD, Kaytlin Krutsch iD

Nutrients · 28.08.2024 · 16 (17) · 2886

DOI: 10.3390/nu16172886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, online erschienen am 28.08.2024. Verfasst von Hanin Diab und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA. Hauptthemen laut MEDLINE: Milk, Human, Breast Feeding, Glucagon-Like Peptides. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: laura bush institute for women's health, Laura W. Bush Institute for Women’s Health at Texas Tech University Health Sciences Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postpartum mothers and their healthcare providers often face the challenge of limited data regarding the safety of drug therapies during lactation. Pregnancy can lead to sustained weight gain, and obesity can negatively impact both physical and psychological well-being. The introduction of GLP-1 agonists to augment weight loss has become a topic of interest for many postpartum mothers. Our study aims to investigate the transmission of semaglutide into human milk in the first steps to ensure the safety and health of both lactating mothers and their breastfed infants. Semaglutide quantification was performed using high-resolution liquid chromatography-mass spectrometry. InfantRisk Center Human Milk biorepository released milk samples from eight women collected at 0, 12 and 24 h post-semaglutide administration. Semaglutide was extracted using protein precipitation in methanol, followed by chromatographic separation. Linear calibration curves for the method ranged between 2.5–30 ng/mL, with a limit of detection of 1.7 ng/mL and a limit of quantification of 5.7 ng/mL (LLOQ). Semaglutide was not detected in any of the collected human milk samples. A worst-case scenario of the relative infant dose (RID) was calculated using the LLOQ as the drug concentration in milk when considering semaglutide’s bioavailability and long-acting dose profile. The maximum RID projected was 1.26%, far below the standard 10% safety threshold. While questions about long-term infant outcomes, the safety of maternal nutrient intake, and the nutrient content of breast milk remain, our findings suggest that semaglutide concentrations in human milk are unlikely to pose clinical concerns for breastfed infants. These results support healthcare providers in making informed decisions regarding postpartum therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Milk, HumanBreast FeedingGlucagon-Like PeptidesHumansFemaleInfant, NewbornAdultLactationInfantSemaglutide

Stichwörter der Autor:innen

GLP-1 analogueGLP-1 receptorbreastfeedinginfant risklactationozempicpharmacologyrybelsussemaglutidewegovy

Substanzen

Glucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA.
  • School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
  • Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.

ORCID-Profile: Hanin Diab, Taylor Fuquay, Ulrich Bickel, Jonathan Thompson, Kaytlin Krutsch

Förderung

  • laura bush institute for women's health
  • Laura W. Bush Institute for Women’s Health at Texas Tech University Health Sciences Center

Zitieren

APA

Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J., & Krutsch, K. (2024). Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients, 16(17), 2886. https://doi.org/10.3390/nu16172886

Vancouver

Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024;16(17):2886. doi:10.3390/nu16172886

BibTeX
@article{Diab2024,
  author = {Diab, Hanin and Fuquay, Taylor and Datta, Palika and Bickel, Ulrich and Thompson, Jonathan and Krutsch, Kaytlin},
  title = {Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {17},
  pages = {2886},
  doi = {10.3390/nu16172886}
}
Kostenlos starten →